Literature DB >> 20064706

Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer.

Cecilia Magnusson1, Maryna Mezhybovska, Ester Lörinc, Eva Fernebro, Mef Nilbert, Anita Sjölander.   

Abstract

Colorectal cancer is the third most common cancer type in the Western world. In search of new treatment possibilities, the inflammation mediators, know as cysteinyl leukotrienes (CysLTs), have been shown to regulate intestinal epithelial cell survival and proliferation via the CysLT(1)R, and cell differentiation via the CysLT(2)R. These results prompted us to investigate the significance of CysLT(1)R and CysLT(2)R expression in colorectal cancer tissue for patient survival. The CysLT(1)R, CysLT(2)R, beta-catenin and Bcl-xL protein expression levels were evaluated by immunohistochemistry in a tissue microarray of 329 colorectal patients. We found that high nuclear expression of CysLT(1)R is associated with a poor prognosis, whereas high nuclear expression of CysLT(2)R is associated with a good prognosis. We also observed that patients with colorectal tumours characterised by high CysLT(1)R but low CysLT(2)R nuclear expression had the lowest survival expectancy, whereas patients with colorectal tumours characterised by low CysLT(1)R but high CysLT(2)R nuclear expression had the best survival expectancy. Interestingly, beta-catenin as a single prognostic marker did not exhibit any prognostic value. However, in patients with tumours characterised by a high CysLT(1)R nuclear expression, an elevated beta-catenin nuclear expression had a significantly prognostic value. In conclusion these data indicate that nuclear expressions of CysLTRs are potential prognostic indicators of colorectal cancer. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20064706     DOI: 10.1016/j.ejca.2009.12.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  35 in total

Review 1.  Eicosanoid signaling in carcinogenesis of colorectal cancer.

Authors:  Yuxin Wang; Weicang Wang; Katherine Z Sanidad; Pei-An Shih; Xinfeng Zhao; Guodong Zhang
Journal:  Cancer Metastasis Rev       Date:  2018-09       Impact factor: 9.264

2.  Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis.

Authors:  Ernest Duah; Lakshminarayan Reddy Teegala; Vinay Kondeti; Ravi K Adapala; Venkateshwar G Keshamouni; Yoshihide Kanaoka; K Frank Austen; Charles K Thodeti; Sailaja Paruchuri
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

3.  Characterization of the cysteinyl leukotriene 2 receptor in novel expression sites of the gastrointestinal tract.

Authors:  Alma Barajas-Espinosa; Fernando Ochoa-Cortes; Michael P Moos; F Daniel Ramirez; Stephen J Vanner; Colin D Funk
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

4.  A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.

Authors:  Clare T Butler; Alison L Reynolds; Miriam Tosetto; Eugene T Dillon; Patrick J Guiry; Gerard Cagney; Jacintha O'Sullivan; Breandán N Kennedy
Journal:  J Biol Chem       Date:  2016-12-29       Impact factor: 5.157

5.  Leukotriene C(4) prevents the complete maturation of murine dendritic cells and modifies interleukin-12/interleukin-23 balance.

Authors:  Carolina Alvarez; María M Amaral; Cecilia Langellotti; Mónica Vermeulen
Journal:  Immunology       Date:  2011-10       Impact factor: 7.397

6.  Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model.

Authors:  Pariya Khodabakhsh; Nilgoon Khoie; Ahmad-Reza Dehpour; Alireza Abdollahi; Mahmoud Ghazi-Khansari; Hamed Shafaroodi
Journal:  Inflammopharmacology       Date:  2022-01-10       Impact factor: 4.473

Review 7.  Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Authors:  Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

8.  Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.

Authors:  Lubna M Mehdawi; Chandra Prakash Prasad; Roy Ehrnström; Tommy Andersson; Anita Sjölander
Journal:  Mol Oncol       Date:  2016-08-01       Impact factor: 6.603

Review 9.  Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer.

Authors:  Sayeh Savari; Katyayni Vinnakota; Yuan Zhang; Anita Sjölander
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 10.  Cysteinyl leukotriene receptors, old and new; implications for asthma.

Authors:  T M Laidlaw; J A Boyce
Journal:  Clin Exp Allergy       Date:  2012-09       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.